Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADAM17 | P78536 | 1/20 | 0.41 |
| ▸ | AR | P10275 | 1/20 | 0.40 |
| ▸ | SLC6A4 | P31645 | 3/20 | 0.39 |
| ▸ | SLC6A3 | Q01959 | 2/20 | 0.39 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.39 |
| ▸ | KDM1A | O60341 | 2/20 | 0.39 |
| ▸ | HCAR3 | P49019 | 1/20 | 0.39 |
| ▸ | HCAR2 | Q8TDS4 | 1/20 | 0.39 |
| ▸ | MMP8 | P22894 | 1/20 | 0.39 |
| ▸ | MMP14 | P50281 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL377317 | 0.78 | LMNA (0.47) | ARKDM1AHCAR3HCAR2 | |
| SCHEMBL715748 | 0.78 | LMNA (0.47) | ARKDM1AHCAR3HCAR2 | |
| SCHEMBL377319 | 0.78 | LMNA (0.47) | ARKDM1AHCAR3HCAR2 | |
| SCHEMBL29949282 | 0.78 | LMNA (0.47) | ARKDM1AHCAR3HCAR2 | |
| SCHEMBL1712712 | 0.78 | LMNA (0.38) | ADAM17SLC6A4KDM1A | |
| SCHEMBL15030417 | 0.78 | MMP14 (0.70) | ADAM17MMP8MMP14 | |
| SCHEMBL3400918 | 0.77 | ADAM17 (0.62) | ADAM17 | |
| SCHEMBL4123231 | 0.77 | ADAM17 (0.62) | ADAM17 | |
| SCHEMBL2191989 | 0.77 | ADAM17 (0.62) | ADAM17 | |
| SCHEMBL20134812 | 0.71 | MMP14 (0.54) | ADAM17MMP8MMP14 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4493546-B1 | IMIDAZOLE DERIVATIVES AS POTASSIUM CHANNEL INHIBITORS | ACESION PHARMA APS (DK) | 2026-05-06 | — | — | EP | disclosed |
| EP-4493546-A1 | IMIDAZOLE DERIVATIVES AS POTASSIUM CHANNEL INHIBITORS | ACESION PHARMA APS (DK) | 2025-01-22 | — | — | EP | disclosed |
| CN-119278197-A | Imidazole derivatives as potassium channel inhibitors | 阿塞西翁制药公司 | 2025-01-07 | — | — | CN | disclosed |
| US-12030856-B2 | Potassium channel inhibitors | ACESION PHARMA APS (DK) | 2024-07-09 | — | — | US | disclosed |
| US-11945811-B2 | Potassium channel inhibitors | ACESION PHARMA APS (DK) | 2024-04-02 | — | — | US | disclosed |
| CN-117561247-A | Novel potassium channel inhibitors | 阿塞西翁制药公司 | 2024-02-13 | — | — | CN | disclosed |
| EP-4313973-A1 | NOVEL POTASSIUM CHANNEL INHIBITORS | Acesion Pharma ApS (DK) | 2024-02-07 | — | — | EP | disclosed |
| US-20230406845-A1 | NOVEL POTASSIUM CHANNEL INHIBITORS | ACESION PHARMA APS (DK) | 2023-12-21 | — | — | US | disclosed |
| US-20230399301-A1 | NOVEL POTASSIUM CHANNEL INHIBITORS | ACESION PHARMA APS (DK) | 2023-12-14 | — | — | US | disclosed |
| US-20230399301-A1 | NOVEL POTASSIUM CHANNEL INHIBITORS | ACESION PHARMA APS (DK) | 2023-12-14 | — | — | US | disclosed |
| US-20230399301-A1 | NOVEL POTASSIUM CHANNEL INHIBITORS | ACESION PHARMA APS (DK) | 2023-12-14 | — | — | US | disclosed |
| WO-2023174836-A1 | IMIDAZOLE DERIVATIVES AS POTASSIUM CHANNEL INHIBITORS | ACESION PHARMA APS (DK) | 2023-09-21 | — | — | WO | disclosed |
| WO-2023174836-A1 | IMIDAZOLE DERIVATIVES AS POTASSIUM CHANNEL INHIBITORS | ACESION PHARMA APS (DK) | 2023-09-21 | — | — | WO | disclosed |
| EP-4245753-A1 | IMIDAZOLE DERIVATIVES AS POTASSIUM CHANNEL INHIBITORS | Acesion Pharma ApS (DK) | 2023-09-20 | — | — | EP | disclosed |
| EP-4245753-A1 | IMIDAZOLE DERIVATIVES AS POTASSIUM CHANNEL INHIBITORS | Acesion Pharma ApS (DK) | 2023-09-20 | — | — | EP | disclosed |
| WO-2022200162-A1 | NOVEL POTASSIUM CHANNEL INHIBITORS | ACECION PHARMA APS (DK) | 2022-09-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12030856-B2 | Potassium channel inhibitors | KCNJ2, KCNN2, KCNN1 | ADAM17 2295/4885AR 2661/4885SLC6A4 629/4885 |
| US-11945811-B2 | Potassium channel inhibitors | KCNJ2, KCNN2, KCNN1 | ADAM17 2295/4885AR 2661/4885SLC6A4 629/4885 |
| US-20230406845-A1 | NOVEL POTASSIUM CHANNEL INHIBITORS | KCNN2, KCNJ2, KCNN1 | ADAM17 2210/4885AR 2902/4885SLC6A4 646/4885 |
| US-20230399301-A1 | NOVEL POTASSIUM CHANNEL INHIBITORS | KCNN2, KCNJ2, KCNN1 | ADAM17 2210/4885AR 2902/4885SLC6A4 646/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.